Europe
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Biopharma companies are preparing to unveil new data for various oncology programs at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans next month.
Venture partnerships won big this week, and genetic therapies-related startups raked in millions. Here’s where the money went.
The single-shot chikungunya vaccine was shown to be safe and effective against mosquito-transmitted chikungunya disease in a published analysis of Phase III results.
Kurma Partners earned €160 million in the first closing of its Growth Opportunities fund, and Atlas Venture raked in its largest round of funding yet to invest in new biotech firms.
Fulcrum Therapeutics will launch a Phase III study of losmapimod in people with facioscapulohumeral muscular dystrophy later this year. Tonix wins Orphan Drug designation for Prader-Willi asset.
A new market research report by InsightAce Analytic projects the immuno-oncology or cancer immunotherapy market will hit $34.69 billion by 2030.
Shares of NuCana have plunged more than 57% in premarket trading after the company announced its Phase III biliary tract cancer study. See more facts here.
Healx brings the power of artifical intelligence (AI) to rare disease research with an ultimate focus on improving patient outcomes.
On Wednesday, Massachusetts-based ConforMIS said it was suspending all distribution of its orthopedic medical devices to Russia and any Russian-based entities.
PRESS RELEASES